Tag Archives: oncology

February, 2016

  • 22 February

    FDA Expands Approval of Pfizer’s Ibrance in Metastatic Breast Cancer

    Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) …

  • 11 February

    Incyte Discontinues Late-Stage Study of its Pancreatic Cancer Combo

    WILMINGTON, Del.–(BUSINESS WIRE)–Feb. 11, 2016– Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after …

  • 5 February

    Amgen’s Blincyto Meets Primary Endpoint in Late-Stage ALL Study

    THOUSAND OAKS, Calif., Feb. 4, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO® (blinatumomab) versus standard of care …

  • 2 February

    GSK and Adaptimmune Expand Immunotherapy Collaboration

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of T-cell receptor (TCR) engineered T-cell therapy to treat cancer, today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell …

January, 2016

  • 27 January

    Cost and Value

    Where does the true value of cancer treatment lie? Oncology experts grapple with this important question, with one of the more recent people to chime in being Robert C. Young, M.D., of RCY Medicine in Philadelphia, in an essay in a recent issue of the New England Journal of Medicine. Dr. …

  • 15 January

    Study of Breast Cancer Cell Function Suggests Several New Potential Drug Targets and Combos

    NEW YORK, Jan. 15, 2016 /PRNewswire-USNewswire/ — The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations. The authors say the study results, published online January 14 in the journal Cell, will be …

  • 13 January

    USPSTF Issues Final Recommendations on Screening for Breast Cancer

    WASHINGTON, D.C. – January 12, 2016 – The U.S. Preventive Services Task Force today published a final recommendation statement on screening for breast cancer following an in-depth review of the science on the benefits and harms of screening mammography, and a detailed review of input received from the public and …

  • 13 January

    Catalent Enters Research Partnership with Roche on SMARTag Technology

    SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products today announced, through its wholly owned subsidiary, Redwood Bioscience, Inc., a research collaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using Catalent’s proprietary SMARTag™ …

  • 8 January

    Roche Announces Encouraging Results from its Bladder Cancer Study

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (MPDL3280A) in people with locally advanced or metastatic urothelial carcinoma (mUC). Median overall survival (mOS) in this heavily pre-treated population was 11.4 months [95% CI: 9.0, …

  • 7 January

    New Drug Shows Promise for Overcoming Treatment Resistance in Childhood Neuroblastoma

    PHILADELPHIA, Jan. 7, 2016 /PRNewswire-USNewswire/ — Pediatric oncologists from The Children’s Hospital of Philadelphia (CHOP) have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. Building on their previous experiences in treating some refractory subtypes of neuroblastoma with the anticancer drug crizotinib, the researchers …